Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients
- PMID: 18510173
- PMCID: PMC2718426
- DOI: 10.1097/cad.0b013e3282f3fd2e
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients
Abstract
The formulation excipient Cremophor EL (CrEL) is known to limit the absorption of oral paclitaxel given together with cyclosporin A. We hypothesized that the use of oral Genetaxyl, a paclitaxel formulation containing only 20% CrEL would have an improved oral bioavailability. Cohorts of six patients were treated with oral Genetaxyl at a dose of 60, 120, or 180 mg/m2 and 10 mg/kg of oral cyclosporin A in cycle 1. In cycle 2, patients received intravenous (i.v.) Genetaxyl (175 mg/m2, 3-h infusion). Three additional patients received one dose of generic i.v. paclitaxel (Genaxol, containing 50% CrEL; 175mg/m2, 3-h infusion). The median area under the plasma concentration-time curve (AUC) and peak concentration of total paclitaxel following i.v. Genetaxyl were lower than those for i.v. Genaxol, as a result of significantly increased clearance (P = 0.017), and the AUC ratio for unbound to total paclitaxel for i.v. Genetaxyl was about two times higher than that for i.v. Genaxol (P = 0.0077). After oral administration of Genetaxyl at doses of 60, 120, and 180 mg/m2, the median total paclitaxel AUCs were 1.29, 1.60, and 1.85 microg x h/ml, respectively, suggesting a less than proportional increase in systemic exposure with increasing doses. The corresponding median values for the apparent bioavailability of oral Genetaxyl were similar when compared with i.v. Genetaxyl, when calculated either on the basis of data for total paclitaxel (30.1%) or unbound paclitaxel (30.6%).
Figures


Similar articles
-
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.Cancer Chemother Pharmacol. 2001 Apr;47(4):347-54. doi: 10.1007/s002800000226. Cancer Chemother Pharmacol. 2001. PMID: 11345652 Clinical Trial.
-
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.J Clin Oncol. 2002 Jan 15;20(2):574-81. doi: 10.1200/JCO.2002.20.2.574. J Clin Oncol. 2002. PMID: 11786588 Clinical Trial.
-
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.Clin Cancer Res. 1999 Nov;5(11):3379-84. Clin Cancer Res. 1999. PMID: 10589748 Clinical Trial.
-
Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.Clin Pharmacokinet. 2018 Jan;57(1):7-19. doi: 10.1007/s40262-017-0563-z. Clin Pharmacokinet. 2018. PMID: 28612269 Free PMC article. Review.
-
Oral delivery of taxanes.Invest New Drugs. 2001 May;19(2):155-62. doi: 10.1023/a:1010635000879. Invest New Drugs. 2001. PMID: 11392449 Review.
Cited by
-
A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.Invest New Drugs. 2013 Jun;31(3):616-22. doi: 10.1007/s10637-012-9841-7. Epub 2012 Jun 14. Invest New Drugs. 2013. PMID: 22695940 Clinical Trial.
-
Preparation, pharmacokinetics, biodistribution, antitumor efficacy and safety of Lx2-32c-containing liposome.PLoS One. 2014 Dec 15;9(12):e114688. doi: 10.1371/journal.pone.0114688. eCollection 2014. PLoS One. 2014. PMID: 25506928 Free PMC article.
-
Pre-ADMET studies of 5-(3',4'-dihydroxyphenyl)-γ-valerolactone, the bioactive intestinal metabolite of proanthocyanidins.Arch Pharm (Weinheim). 2025 Jan;358(1):e2400575. doi: 10.1002/ardp.202400575. Epub 2024 Nov 11. Arch Pharm (Weinheim). 2025. PMID: 39526505 Free PMC article.
-
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).Pharmacogenet Genomics. 2011 Mar;21(3):152-61. doi: 10.1097/FPC.0b013e3283385a1c. Pharmacogenet Genomics. 2011. PMID: 20216335 Free PMC article. No abstract available.
-
Sol-moiety: Discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics.Nat Commun. 2024 Oct 1;15(1):8487. doi: 10.1038/s41467-024-52793-6. Nat Commun. 2024. PMID: 39353935 Free PMC article.
References
-
- Estevez LG, Munoz M, Alvarez I, Fernandez Y, Garcia-Mata J, Ruiz-Borrego M, et al. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treat Rev. 2007;33:474–483. - PubMed
-
- Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Taxanes as first-line treatment for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer. 2005;50:355–374. - PubMed
-
- Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33(2 Supl 6):S3–S11. - PubMed
-
- Hait WN, Rubin E, Goodin S. Tubulin-targeting agents. Cancer Chemother Biol Response Modif. 2003;21:41–67. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources